Marshall Wace, LLP Collegium Pharmaceutical, Inc Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$31.36 - $39.99 $2.23 Million - $2.84 Million	70,964 New	70,964 $2.29 Million
Q4 2023 Feb 14, 2024	SELL	$21.16 - $30.8 $5.3 Million - $7.71 Million	-250,247 Reduced 64.78%	136,049 $4.19 Million
Q3 2023 Nov 14, 2023	SELL	$21.23 - $24.28 $2.3 Million - $2.63 Million	-108,180 Reduced 21.88%	386,296 $8.63 Million
Q2 2023 Aug 14, 2023	SELL	$21.06 - $24.0 $1.8 Million - $2.05 Million	-85,435 Reduced 14.73%	494,476 $10.6 Million
Q1 2023 May 15, 2023	BUY	$23.0 - $29.88 $6.28 Million - $8.15 Million	272,881 Added 88.88%	579,911 $13.9 Million
Q4 2022 Feb 14, 2023	BUY	$16.14 - $23.55 $4.31 Million - $6.29 Million	267,065 Added 668.25%	307,030 $7.12 Million
Q3 2022 Nov 14, 2022	BUY	$15.46 - $20.1 $617,858 - $803,296	39,965 New	39,965 $640,000
Q2 2021 Aug 13, 2021	BUY	$21.74 - $25.28 $254,749 - $296,231	11,718 New	11,718 $277,000
Q2 2019 Aug 14, 2019	SELL	$10.62 - $16.59 $604,925 - $944,982	-56,961 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$13.58 - $18.72 $773,530 - $1.07 Million	56,961 New	56,961 $862,000

255

38.6M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.01B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.